NL-OMON44863已完成2 期
A randomized phase II trial of pertuzumab in combination with trastuzumab with or without chemotherapy, both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer - PERNETTA
ICANCER0 个研究点目标入组 26 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 26
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Histologically confirmed breast cancer with distant metastases;Notes :;1. A biopsy from the primary tumor or a metastasis can be used for diagnosis.;2. Patients with non-measurable lesions are eligible.;3. Patients with inoperable, locally advanced breast cancer with lymph node metastases other than ipsilateral locoregional (axillary, infraclavicular, parasternal) or other distant metastases are eligible.;4. Patients with bone metastases with or without bone targeted therapy (bisphosphonates, denosumab) are eligible.;5. Patients with de-novo Stage IV disease are eligible.;- HER2-positive tumor according to central pathology testing for HER2;Note:;1. A formalin-fixed paraffin-embedded (FFPE) biopsy from the primary tumor or a metastasis has to be used for HER2 status determination. If a biopsy is available from a metastasis, the HER2 testing should be performed using the metastasis.;2. Fine needle aspiration is not acceptable for HER 2 testing.;- Women aged *18 years;- WHO performance status 0 to 2 (see Appendix 2);- Left Ventricular Ejection Fraction (LVEF) *50% as determined by either ECHO or MUGA;- Adequate organ function, evidenced by the following laboratory results:;Neutrophils >1.5x10^9/L, platelets >100x10^9/L, hemoglobin *90g/L, total bilirubin *1.5xULN (unless the patients has documented Gilbert*s disease), AST*3xULN, ALT *3xULN, AP *2.5xULN (except in patients with bone metastases: AP *5xULN), creatinine *1.5xULN;- At least one dose of trial therapy in the first-line treatment phase of this trial;- Proven disease progression on first-line therapy or radiotherapy of a bone metastasis;Notes:;First new parenchymal CNS metastases only do not count as progression requiring the initiation of second line trial treatment (please see Appendix 1.4, Determination and evaluation of new lesions).;Radiotherapy of a single area only for pain control is allowed and will not count as PD.;- Adequate organ function, evidenced by the following laboratory results:;Neutrophils >1.5x10^9/L, platelets >100x10^9/L, hemoglobin *90g/L, total bilirubin *1.5xULN (unless the patients has documented Gilbert*s disease), AST *3xULN, ALT *3xULN, AP *2.5xULN (except in patients with bone metastases: AP *5xULN), creatinine *1.5ULN;- LVEF *50% as determined by either ECHO or MUGA;- QoL questionnaire has been completed.;- Negative serum pregnancy test in women of childbearing potential
排除标准
- •- Prior chemotherapy for inoperable locally advanced or metastatic breast cancer;Note:;Prior neoadjuvant/adjuvant chemotherapy is allowed if doses for anthracylines have not exceeded 720mg/m2 and 240mg/m2 for epirubicin and doxorubicin, respectivel.;- Reexposure to paclitaxel is permitted, if the last dose of taxane was given at least 1 year before randomisation.;- Reexposure to vinorelbine is permitted, if the last dose of vinorelbine was given at least 1 year before randomisation.;- Prior anti-HER2 treatment for metastatic or inoperable breast cancer;Note:;Prior neoadjuvant/adjuvant anti-HER2 treatment with trastuzumab and/or lapatinib is allowed.;- More than one endocrine treatment line for metastatic or inoperable breast cancer exceeding a duration of 1 month;Note:;1. Adjuvant endocrine treatment is not counted as one line.;2. Patients progressing on endocrine treatment: this specific endocrine treatment must have been stopped at least 2 weeks prior to randomization.;- Prior treatment with pertuzumab and/or T-DM1;- Known leptomeningeal or CNS metastases;Note:;A brain MRI or CT scan is mandatory in case of clinical suspicion of CNS metastases.;- Single bone metastasis treated with radiotherapy (if the bone metastasis is the only tumor lesion);- Termination of first-line therapy with trastuzumab/pertuzumab due to unacceptable toxicity without objective evidence of disease progression;- CNS metastases that are untreated, symptomatic, or require therapy to control symptoms, as well as a history of radiation, surgery, or other therapy, including steroids, to control symptoms from CNS metastases within 2 months (60 days) before registration;- Peripheral neuropathy of CTCAE grade *3;- Interstitial lung disease (ILD) or pneumonitis grade *4;- Any other adverse event which has not recovered to CTCAE grade *1 (except alopecia)
研究者
相似试验
进行中（未招募）
1 期
A randomized phase II trial of pertuzumab in combination with trastuzumab with or without chemotherapy, both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer - PERNETTAEUCTR2012-002556-17-FRICANCER208
进行中（未招募）
1 期
_EUCTR2012-002556-17-DEICANCER208
进行中（未招募）
1 期
A randomized phase II trial of pertuzumab in combination with trastuzumab with or without chemotherapy, both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer - PERNETTAHER2-positive metastatic breast cancerMedDRA version: 19.1Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002556-17-NLICANCER208
已完成
2 期
A phase II trial of pertuzumab and trastuzumab in combination with capecitabine in patients with metastatic breast cancer who received prior trastuzumab combination chemotherapy.Breast cancerJPRN-UMIN000012208Kurume University Hospital24
已完成
2 期
Phase II Trial of Pertuzumab plus Trastuzumab plus Docetaxel for HER2-Positive Metastatic Breast Cancer that Progressed During Prior Trastuzumab TherapyHER2-Positive Metastatic Breast CancerJPRN-UMIN000012452Chiba Youth Breast Oncology Research Group (CYBORG)35